Drugs and Chemicals of
Concern > 5-Methoxy-N,N-diisopropyltryptamine
(5-MeO-DIPT)
5-METHOXY-N,N-DIISOPROPYLTRYPTAMINE
(Street Names: Foxy, or Foxy methoxy)
June 2009
DEA/OD/ODE
Introduction:
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a
tryptamine derivative and shares many similarities with schedule
I tryptamine hallucinogens such as alpha-ethyltryptamine,
N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine,
psilocybin and psilocin. Since 1999, there has been a
growing popularity of 5-MeO-DIPT among drug abusers. This
substance is abused for its hallucinogenic effects.
Licit Uses:
5-MeO-DIPT has no approved medical uses in the United States.
Chemistry/Pharmacology:
5-MeO-DIPT is a tryptamine derivative. The
hydrochloride salt of 5-MeO-DIPT is a white crystalline powder.
In animal behavioral studies, 5-MeO-DIPT has been shown to
produce behavioral effects that are substantially similar to
those of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM)
and lysergic acid diethylamide (LSD), both schedule I
hallucinogens.
In humans, 5-MeO-DIPT elicits subjective effects including
hallucinations similar to those produced by several schedule I
hallucinogens such as 2C-B and
4-ethyl-2,5-dimethoxyphenyl-isopropylamine (DOET). The
threshold dose of 5-MeO-DIPT to produce psychoactive effects is
4 mg, while effective doses range from 6 to 20 mg. 5-MeO-DIPT
produces effects with an onset of 20 to 30 minutes and with peak
effects occurring between 1 to 1.5 hours after administration.
Effects last about 3 to 6 hours. Initial effects include
mild nausea, muscular hyperreflexia, and dilation of pupils.
Other effects include relaxation associated with emotional
enhancement, talkativeness and behavioral disinhibition. High
doses of 5-MeO-DIPT produce abstract eyes-closed imagery. 5-MeO-DIPT
alters sensory perception and judgment and can pose serious
health risks to the user and the general public. Abuse of
5-MeO-DIPT led to at least one emergency department admission.
Illicit Uses:
5-MeO-DIPT is abused for its hallucinogenic-like effects and
is used as a substitute for MDMA. It is often administered
orally as either powder, tablets or capsules at doses ranging
from 6-20 mg. Other routes of administration include
smoking and snorting. Tablets often bear imprints commonly
seen on MDMA tablets (spider and alien head logos) and vary in
color. Powder in capsules was found to vary in colors.
User Population:
Youth and young adults are the main abusers of 5-MeO-DIPT.
Illicit Distribution:
According to National Forensic Laboratory Information System
(NFLIS), law enforcement agents submitted 35 5-MeO-DIPT items to
federal laboratories for analysis between 2004 and 2008.
Most of the items (19) were submitted in 2008. State and
local labs received 214 drug items during that same time period.
The number of 5-MeO-DIPT drug item seizures increased from 61 in
2007 to 135 in 2008.
5-MeO-DIPT has been illicitly available from United States
and foreign chemical companies and from individuals through the
Internet. There is some evidence of the attempted
clandestine production of 5-MeO-DIPT.
Control Status:
The Drug Enforcement Administration (DEA) placed 5-MeO-DIPT
temporarily in schedule I of the Controlled Substances Act (CSA)
on April 4, 2003, pursuant to the temporary scheduling
provisions of the CSA (68 FR 16427). On September 29,
2004, 5-MeO-DIPT was controlled as schedule I substance under
the CSA (69 FR 58050).
Comments and additional information are welcomed by the
Drug and Chemical Evaluation Section.
Fax 202-353-1263, telephone 202-307-7183, or Email ODE@usdoj.gov.
|